Physician profile
Brian H Perlmutter
NPI 1851479380
$6,114.61
in general payments reported to CMS, 2019-2025
32 companies · $642 in 2025
The $642 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,794 · 2020: $879 · 2021: $692 · 2022: $1,127 · 2023: $610 · 2024: $370 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,622.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,132.22 | 2019-2025 | Lifevest |
| Abbott Laboratories | $706.38 | 2019-2025 | Triclip |
| Novartis Pharmaceuticals Corporation | $551.10 | 2019-2024 | |
| Abiomed | $520.63 | 2019-2023 | Impella |
| Edwards Lifesciences Corporation | $429.25 | 2019-2025 | Sapien 3 Ultra Resilia |
| Medtronic Vascular, INC. | $340.35 | 2019-2020 | |
| Boston Scientific Corporation | $333.86 | 2019-2025 | Accolade Sr, General - Therapies, General - Atherectomy |
| Medtronic, INC. | $245.10 | 2021-2022 | |
| Biotronik INC. | $201.62 | 2019-2020 | |
| Astellas Pharma US INC | $198.47 | 2019-2021 | |
| Amgen INC. | $178.94 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $169.96 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.71 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $120.47 | 2019-2025 | Farxiga |
| Pfizer INC. | $111.18 | 2020-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $89.65 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $86.08 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $85.20 | 2019-2021 | |
| Amarin Pharma, INC. | $64.13 | 2020 | |
| Terumo Medical Corporation | $62.99 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $53.58 | 2019-2025 | Opsumit |
| Merck Sharp & Dohme LLC | $48.50 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $42.60 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $24.97 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $24.60 | 2019 | |
| Cordis US Corp. | $23.40 | 2023 | Mynx Control |
| Lundbeck LLC | $22.87 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.57 | 2025 | |
| Kestra Medical Technology Services, INC. | $19.35 | 2025 | Assure Wcd |
| Cook Medical LLC | $18.10 | 2019 | |
| Bardy Diagnostics, INC. | $15.00 | 2022 | |
| Atricure, INC. | $12.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Perlmutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.